The impact of nirmatrelvir-ritonavir in reducing hospitalizations among high-risk patients with SARS-CoV-2 during the omicron predominant era
MM Al-Obaidi, AB Gungor, S Murugapandian… - The American Journal of …, 2023 - Elsevier
Background The coronavirus disease 2019 (COVID-19) pandemic has caused significant
morbidity and mortality in high-risk populations. Several therapeutics have been developed …
morbidity and mortality in high-risk populations. Several therapeutics have been developed …
No statistically apparent difference in antiviral effectiveness observed among ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus …
YQ Huang, SQ Tang, XL Xu, YM Zeng, XQ He… - Frontiers in …, 2020 - frontiersin.org
Background Currently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
spread globally, causing an unprecedented pandemic. However, there is no specific …
spread globally, causing an unprecedented pandemic. However, there is no specific …
No benefit for lopinavir–ritonavir in severe COVID-19
A Slomski - Jama, 2020 - jamanetwork.com
No Benefit for Lopinavir–Ritonavir in Severe COVID-19 | Critical Care Medicine | JAMA | JAMA
Network [Skip to Navigation] Our website uses cookies to enhance your experience. By continuing …
Network [Skip to Navigation] Our website uses cookies to enhance your experience. By continuing …
Rebound of SARS-CoV-2 infection after nirmatrelvir–ritonavir treatment
ME Charness, K Gupta, G Stack… - … England Journal of …, 2022 - Mass Medical Soc
Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment | New England Journal
of Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
of Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
Rebound phenomenon after nirmatrelvir/ritonavir treatment of coronavirus disease 2019 (COVID-19) in high-risk persons
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2
patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced …
patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced …
Association of nirmatrelvir for acute SARS‐CoV‐2 infection with subsequent Long COVID symptoms in an observational cohort study
MS Durstenfeld, MJ Peluso, F Lin… - Journal of Medical …, 2024 - Wiley Online Library
Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID‐19, but the effect of
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
S Ombelet, D Castanares‐Zapatero… - Journal of medical …, 2024 - Wiley Online Library
Nirmatrelvir‐ritonavir (NR) was approved to treat SARS‐CoV‐2 positive outpatients at high
risk of progression to severe disease, based on a randomized trial in unvaccinated patients …
risk of progression to severe disease, based on a randomized trial in unvaccinated patients …
[HTML][HTML] Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis
T Pitre, R Van Alstine, G Chick, G Leung, D Mikhail… - Cmaj, 2022 - Can Med Assoc
Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …
The effect of nirmatrelvir‐ritonavir on viral clearance and length of hospital stay in patients infected with SARS‐CoV‐2 omicron variants
Y Wang, D Zhao, X Chen, X Liu… - Influenza and other …, 2023 - Wiley Online Library
Background The pandemic of coronavirus disease 2019 (COVID‐19) has caused heavy
burdens on national healthcare systems. Nirmatrelvir‐ritonavir (Paxlovid) may be one of the …
burdens on national healthcare systems. Nirmatrelvir‐ritonavir (Paxlovid) may be one of the …
Efficacy and safety of lopinavir/ritonavir for treatment of COVID-19: a systematic review and meta-analysis
S Alhumaid, A Al Mutair, Z Al Alawi, N Alhmeed… - Tropical medicine and …, 2020 - mdpi.com
(Background) Lopinavir-ritonavir (LPV/RTV) is a human immunodeficiency virus (HIV)
antiviral combination that has been considered for the treatment of COVID-19 disease.(Aim) …
antiviral combination that has been considered for the treatment of COVID-19 disease.(Aim) …